Breast Cancer Clinical Trial
— DISCOOfficial title:
DISCO: A Patient Intervention to Reduce the Financial Burden of Cancer
The DISCO App is designed to improve, during the interaction, patient active participation and patient-initiated oncologist treatment cost discussions, and, in the short term, patient's treatment cost knowledge, self-efficacy for managing both cost and physician interactions, referrals, perceived financial toxicity (i.e., distress and material hardship); in turn, these will affect longer-term outcomes of financial toxicity and adherence.
Status | Recruiting |
Enrollment | 260 |
Est. completion date | August 31, 2025 |
Est. primary completion date | August 31, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Oncologists are eligible if they treat patients with breast, prostate, lung, or colorectal cancers at Karmanos Cancer Institute. Data from oncologists will include their self-report data and video-recorded treatment discussions with participating patients. - Patients: Must be able to read and write in English; have an email account; and are newly diagnosed with breast, prostate, lung or colorectal cancer (stage I-IV) for which systemic therapy is a likely recommended treatment. Data from patients will include their self-report data, video-recorded treatment discussions with participating oncologists, and medical record data Exclusion Criteria: - |
Country | Name | City | State |
---|---|---|---|
United States | Barbara Ann Karmanos Cancer Institute | Detroit | Michigan |
Lead Sponsor | Collaborator |
---|---|
Lauren Hamel |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Assessment of the intervention. | Patient perceptions of the intervention's usefulness using an original scale.
An example item from the original measure: The DISCO App helped me ask my doctor my cost questions. Minimum = 1; Maximum = 5; higher is a better outcome. |
Immediately after video-recorded patient-physician interaction | |
Other | Assessment of the intervention booster An example item from the original measure: The reminder email or text message was helpful with my cost questions and concerns. | Patient perceptions of the intervention booster's usefulness | 1 month after the video-recorded patient-physician interaction | |
Other | Intervention presence in video-recorded patient-physician interaction | If the interaction is visible in the video-recorded patient-physician interaction | During the video-recorded patient-physician interaction | |
Primary | Self-efficacy in patient-physician interactions. An example item from the PEPPI scale: How confident are you in your ability to know what questions to ask your doctor? Data will be aggregated using means and standard deviations. | How efficacious patients feel about communicating with physicians. Scale title: Self-efficacy in patient-physician interactions. Minimum = 1; Maximum = 5; higher is a better outcome. | Immediately after the video-recorded patient-physician interaction | |
Primary | Self-efficacy in managing treatment costs An example item from adapted scale: I am confident I can pay for the direct costs of my treatment. Data will be aggregated using means and standard deviations. | How efficacious patients feel about managing their treatment costs. Scale title: Self-efficacy in managing treatment costs. Minimum = 1; Maximum = 5; higher is a better outcome. | Immediately after video-recorded patient-physician interaction | |
Primary | Knowledge of types of treatment cost An example item from the original measure: Cancer treatment may cost me in the following ways? Data will be aggregated using frequency counts. | If patients know the types of cost associated with cancer treatment | Immediately after video-recorded patient-physician interaction | |
Primary | Perceived financial toxicity; Scale title: Adapted Comprehensive score for financial toxicity (COST) measure. | Anticipated financial harm due to treatment cost. Scale title: Adapted Comprehensive score for financial toxicity (COST) measure. Minimum = 0; Maximum = 4; lower is a better outcome. | Immediately after video-recorded patient-physician interaction | |
Primary | Perceived presence of treatment cost discussion | Patient perception that treatment cost discussed with the physician | Immediately after video-recorded patient-physician interaction | |
Primary | Patient self-report of level of satisfaction with any treatment cost discussions with physician assessed via an original scale: satisfaction with any treatment cost discussed with the physician that occurred. | Scale title: Satisfaction with any treatment cost discussed with the physician that occurred. Minimum = 1; Maximum = 5; higher is a better outcome. | Immediately after video-recorded patient-physician interaction | |
Primary | The observed frequency of a cost discussion assessed via an original coding system. Frequency is assessed as the number of distinct cost discussions that occur in each recorded interaction. Higher is a better outcome. | Observation of the frequency of a cost discussion. Minimum = 0; Maximum = undefined. | During the video-recorded patient-physician interaction | |
Primary | Patient-Centered Communication scale. The observed quality of patient-physician communication assessed a validated coding system. Minimum = 1; Maximum =5; higher is a better outcome | Observation of the quality of patient-physician communication. | During the video-recorded patient-physician interaction | |
Primary | Referral to social work/financial navigator | If the patient was referred to a social worker or financial navigator. The number of patients who receive a referral to a social worker or a financial navigator. | Immediately after video-recorded patient-physician interaction | |
Secondary | Self-efficacy in patient-physician interactions. An example item from the PEPPI scale: How confident are you in your ability to know what questions to ask your doctor? Data will be aggregated using means and standard deviations. | How efficacious patients feel about communicating with physicians. Scale title: Self-efficacy in patient-physician interactions. Minimum = 1; Maximum = 5; higher is a better outcome. | 1, 3, 6, and 12 months after video-recorded patient-physician interaction | |
Secondary | Self-efficacy in managing treatment costs | How efficacious patients feel about managing their treatment costs. Scale title: Self-efficacy in managing treatment costs. Minimum = 1; Maximum = 5; higher is a better outcome.
An example item from the adapted scale: I am confident I can pay for the direct costs of my treatment. Data will be aggregated using means and standard deviations. |
1, 3, 6, and 12 months after video-recorded patient-physician interaction | |
Secondary | Financial toxicity | The experience of financial harm due to treatment cost. Rate of patients who indicate they are experiencing financial burden due to cancer treatment costs. | 1, 3, 6, and 12 months after video-recorded patient-physician interaction | |
Secondary | Follow up with social work/financial navigator | If the patient followed up with social work/financial navigator if referred.
Data will be aggregated using frequency counts. |
1, 3, 6, and 12 months after video-recorded patient-physician interaction | |
Secondary | Treatment adherence An example item from the Medical Outcomes Study General Adherence measure: I had a hard time doing what the doctor suggested I do for treating my cancer. | If the patient adhered to the recommended treatment | 1, 3, 6, and 12 months after video-recorded patient-physician interaction | |
Secondary | Treatment-cost related adherence | If the patient was unable to adhere to treatment due to cost | 1, 3, 6, and 12 months after video-recorded patient-physician interaction | |
Secondary | Clinical appointment adherence. The rate of appointments a patient is scheduled for and attends. | If the patient adhered to clinical appointments | 1, 3, 6, and 12 months after video-recorded patient-physician interaction |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A |